Relmada Therapeutics Inc. reported a net loss of $57,385,163, or $1.45 per common share, for the year ended December 31, 2025, and had negative operating cash flows of $45,786,988.
Bullish
Relmada Therapeutics Inc. diversified its pipeline with NDV-01 and sepranolone, showing favorable Phase 2 NDV-01 data and FDA alignment for Phase 3, while securing significant funding to support ongoing operations.
Bearish
Relmada Therapeutics Inc. faces substantial losses and uncertain future profitability, with new drug candidates in early, high-risk development; intense competition and evolving healthcare reforms further challenge its business.